Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 151

Sort by

Sort Order Select

Journal Articles

A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma

Hayder Saeed, Melanie Mediavilla Varela, Eva Sahakian, Mahrukh Naqvi, Qiangxing Mo, Ling Zhang, Rikesh Makanji, Yumeng Zhang, Ning Dong, Leidy Lismeris Isenalumhe, Sameh Gaballa, Julio C. Chavez, Bijal D Shah, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 3065.

https://doi.org/10.1182/blood-2024-205173

Published: 2024

Journal Articles

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

Blood (2024) 144 (Supplement 1): 4578.

https://doi.org/10.1182/blood-2024-210599

Published: 2024

Journal Articles

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Mohammad Ammad Ud Din, Katherine Tobon, Julio C. Chavez, Lisa Nodzon, Hayder Saeed, Sameh Gaballa, Ning Dong, Leidy Lismeris Isenalumhe, Celeste M. Bello, Ariel Grajales-Cruz, Kenneth H. Shain, Lubomir Sokol, Bijal D Shah, Javier Pinilla-Ibarz

Blood (2024) 144 (Supplement 1): 6778.

https://doi.org/10.1182/blood-2024-208769

Published: 2024

Journal Articles

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Blood (2024) 144 (Supplement 1): 1609.

https://doi.org/10.1182/blood-2024-200587

Published: 2024

Journal Articles

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Blood (2024) 144 (Supplement 1): 466.

https://doi.org/10.1182/blood-2024-194796

Published: 2024

Journal Articles

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Jia Ruan, Evelyn H. Orlando, Alison Moskowitz, Zhengming Chen, Neha Mehta-Shah, Lubomir Sokol, Steven Horwitz, Sarah C. Rutherford, Tejasvi Sahni, Ari M Melnick, Giorgio Inghirami, Leandro Cerchietti, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 1693.

https://doi.org/10.1182/blood-2024-206606

Published: 2024

Journal Articles

Impact of Clonal T-LGL Populations in Peripheral Blood on Clinical Outcomes in Cutaneous T-Cell Lymphoma

Sara Niyazi, Xiaoqing Yu, Carly Harro, Lewis Glass, Lubomir Sokol, Jose Conejo-Garcia, Ling Zhang, Yumeng Zhang

Blood (2024) 144 (Supplement 1): 3060.

https://doi.org/10.1182/blood-2024-202658

Published: 2024

Journal Articles

A Retrospective Study of Extracorporeal Photopheresis (ECP) in Treatment of Cutaneous T-Cell Lymphoma (CTCL) Evaluating Global, Skin and Blood Responses

Ning Dong, Shubham Jaiswal, Sushmita Khadka, Cathelencia Francisque, Yumeng Zhang, Lewis Glass, Kaaron Benson, Hien Liu, Lubomir Sokol

Blood (2023) 142 (Supplement 1): 3078.

https://doi.org/10.1182/blood-2023-191313

Published: 2023

Journal Articles

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study

Mohammad Ammad Ud Din, Todd C Knepper, Julio C. Chavez, Lisa Nodzon, Hayder Saeed, Sameh Gaballa, Lubomir Sokol, Ning Dong, Leidy Lismeris Isenalumhe, Celeste M. Bello, Bijal D. Shah, Javier Pinilla-Ibarz

Blood (2023) 142 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2023-179658

Published: 2023

Journal Articles

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

Aditi Saha, Junmin Whiting, Mohammad Ammad-ud-din, Cole Powell, Kristen Flores, Felix Sanjay, Humaira Sarfraz, Khushali Jhaveri, Michael V. Jaglal, Katherine Tobon, Hayder Saeed, Celeste M. Bello, Bijal D. Shah, Leidy Lismeris Isenalumhe, Javier Pinilla-Ibarz, Lubomir Sokol, Julio C Chavez, Ning Dong

Blood (2023) 142 (Supplement 1): 1750.

https://doi.org/10.1182/blood-2023-188211

Published: 2023

Journal Articles

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Ning Dong, Hailing Zhang, Jinming Song, Jamila Mammadova, Bijal D. Shah, Hayder Saeed, Ariel F. Grajales-Cruz, Leidy Lismeris Isenalumhe, Sameh Gaballa, Celeste M. Bello, Lubomir Sokol, Javier Pinilla-Ibarz, Julio C Chavez

Blood (2023) 142 (Supplement 1): 3138.

https://doi.org/10.1182/blood-2023-184779

Published: 2023

Journal Articles

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Jonathan E. Brammer, Karen Ballen, Lubomir Sokol, Christiane Querfeld, Ryotaro Nakamura, Anjali Mishra, Eric M. McLaughlin, David Feith, Nazli Azimi, Thomas A. Waldmann, Yutaka Tagaya, Thomas Loughran

Blood (2023) 142 (15): 1271–1280.

https://doi.org/10.1182/blood.2022017643

Published: 2023

Includes: Supplemental data

Journal Articles

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Blood (2023) 141 (18): 2194–2205.

https://doi.org/10.1182/blood.2022018254

Published: 2023

Includes: Supplemental data

Journal Articles

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

Blood (2023) 141 (9): 1036–1046.

https://doi.org/10.1182/blood.2021013489

Published: 2023

Includes: Supplemental data

Journal Articles

Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)

Bei Hu, Shebli Atrash, Leah Cohen, Stefan K. Barta, Yumeng Zhang, Lubomir Sokol, Amy Ayers, Luis E Malpica Castillo, Steven R Hwang, N. Nora Bennani, David Wada, Aung M Tun, Tamara K. Moyo, Nilanjan Ghosh, Michi M Shinohara

Blood (2022) 140 (Supplement 1): 1488–1490.

https://doi.org/10.1182/blood-2022-166887

Published: 2022

Journal Articles

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Blood (2022) 140 (Supplement 1): 1481–1484.

https://doi.org/10.1182/blood-2022-160090

Published: 2022

Journal Articles

Efficacy of Combinatorial Treatment Approaches in CTCL

Melanie Mediavilla-Varela, Eva Sahakian, Carly Harro, John J. Powers, Jose Conejo-Garcia, Lubomir Sokol, Javier Pinilla Ibarz

Blood (2022) 140 (Supplement 1): 11880–11881.

https://doi.org/10.1182/blood-2022-169915

Published: 2022

Journal Articles

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Ashley Rose, Jennifer Eatrides, Hayder Saeed, Bijal D. Shah, Aleksandr Lazaryan, Farhad Khimani, Javier Pinilla Ibarz, Hien D. Liu, Frederick L. Locke, Michael D. Jain, Mohamed A. Kharfan-Dabaja, Jongphil Kim, Ling Zhang, Ernesto Ayala, Taiga Nishihori, Lubomir Sokol

Blood (2022) 140 (Supplement 1): 6569–6570.

https://doi.org/10.1182/blood-2022-168347

Published: 2022

Journal Articles

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

Yumeng Zhang, Jennifer Eatrides, Ashley Rose, Ling Zhang, Farhad Khimani, Aleksandr Lazaryan, Bijal D. Shah, Hayder Saeed, Michael D. Jain, Hien D. Liu, Frederick L. Locke, Javier Pinilla Ibarz, Jongphil Kim, Mohamed A. Kharfan-Dabaja, Ernesto Ayala, Lubomir Sokol, Taiga Nishihori

Blood (2022) 140 (Supplement 1): 10634–10636.

https://doi.org/10.1182/blood-2022-169200

Published: 2022

Journal Articles

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Blood (2021) 138 (Supplement 1): 138.

https://doi.org/10.1182/blood-2021-145495

Published: 2021

NARROW

A Phase I Study of Duvelisib in Combination with Oral Azacitidine (BMS-986345) in Mature T Cell Lymphoma

Synchronous Dual Hematologic Neoplasms of Myeloid and Lymphoid Lineage Are of Common Clonal Origin

The Real-World Safety and Tolerability of Pirtobrutinib Among Patients with B Cell Lymphomas; A Single Center Experience

Lacutamab in Patients with Relapsed and/or Refractory Sézary Syndrome: Translational Analysis from the Tellomak Phase 2 Trial

Health-Related Quality of Life in Patients with Relapsed/Refractory Cutaneous T-Cell Lymphoma Treated By Lacutamab: Patient-Reported Outcomes from the Phase 2 Tellomak Trial

Subsequent Treatment and Clinical Outcome Following Induction Therapy on a Phase II Study of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL)

Impact of Clonal T-LGL Populations in Peripheral Blood on Clinical Outcomes in Cutaneous T-Cell Lymphoma

A Retrospective Study of Extracorporeal Photopheresis (ECP) in Treatment of Cutaneous T-Cell Lymphoma (CTCL) Evaluating Global, Skin and Blood Responses

Clinical Characteristics, Treatment Strategies, and Outcomes for CLL Patients with BTK Mutation; A Single Center Study

A Retrospective Study on Outcomes of Secondary CNS Lymphoma: Pattern of Relapse, Prognostic Factors, and Role of Consolidation Therapy

B-Cell Maturation Antigen (BCMA) Expression and Clinical Features of Plasmablastic Lymphoma (PBL)

Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia

Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL

Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients

Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)

CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Efficacy of Combinatorial Treatment Approaches in CTCL

Autologous Hematopoietic Cell Transplant Consolidation for First Response Is Associated with Longer Survival in Patients with Nodal Peripheral T-Cell Lymphoma

Comparing Survival Outcomes of Autologous and Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed/Refractory Nodal Peripheral T-Cell Lymphoma

High Rates of Remission with the Initial Treatment of Oral Azacitidine Plus CHOP for Peripheral T-Cell Lymphoma (PTCL): Clinical Outcomes and Biomarker Analysis of a Multi-Center Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only